Guangdong Zhongsheng Pharmaceutical Co Ltd - Asset Resilience Ratio
Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) has an Asset Resilience Ratio of 6.62% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002317 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Guangdong Zhongsheng Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002317 asset base.
Liquid Assets Composition Over Time
This chart breaks down Guangdong Zhongsheng Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Guangdong Zhongsheng Pharmaceutical Co L's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥342.12 Million | 6.62% |
| Total Liquid Assets | CN¥342.12 Million | 6.62% |
Asset Resilience Insights
- Limited Liquidity: Guangdong Zhongsheng Pharmaceutical Co Ltd maintains only 6.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guangdong Zhongsheng Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangdong Zhongsheng Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
Annual Asset Resilience Ratio for Guangdong Zhongsheng Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Guangdong Zhongsheng Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.51% | CN¥305.99 Million ≈ $44.78 Million |
CN¥5.55 Billion ≈ $812.65 Million |
-5.07pp |
| 2023-12-31 | 10.58% | CN¥683.06 Million ≈ $99.95 Million |
CN¥6.46 Billion ≈ $945.08 Million |
+4.68pp |
| 2022-12-31 | 5.90% | CN¥340.68 Million ≈ $49.85 Million |
CN¥5.78 Billion ≈ $845.11 Million |
+1.00pp |
| 2021-12-31 | 4.89% | CN¥239.92 Million ≈ $35.11 Million |
CN¥4.90 Billion ≈ $717.31 Million |
-1.53pp |
| 2020-12-31 | 6.42% | CN¥306.65 Million ≈ $44.87 Million |
CN¥4.78 Billion ≈ $698.89 Million |
+6.04pp |
| 2018-12-31 | 0.38% | CN¥20.00 Million ≈ $2.93 Million |
CN¥5.24 Billion ≈ $767.41 Million |
-5.78pp |
| 2017-12-31 | 6.16% | CN¥299.00 Million ≈ $43.75 Million |
CN¥4.86 Billion ≈ $710.60 Million |
-- |
| 2016-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥4.23 Billion ≈ $618.31 Million |
-- |
| 2015-12-31 | 5.55% | CN¥185.00 Million ≈ $27.07 Million |
CN¥3.33 Billion ≈ $487.87 Million |
-15.70pp |
| 2014-12-31 | 21.25% | CN¥490.00 Million ≈ $71.70 Million |
CN¥2.31 Billion ≈ $337.49 Million |
-- |
About Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is based in Dongguan, China.